The Brugada Syndrome: A Rare Arrhythmia Disorder with Complex Inheritance by Jean-Baptiste Gourraud et al.
April 2016 | Volume 3 | Article 91
Review
published: 25 April 2016
doi: 10.3389/fcvm.2016.00009
Frontiers in Cardiovascular Medicine | www.frontiersin.org
Edited by: 
Matteo Vatta, 
Indiana University, USA
Reviewed by: 
Marina Cerrone, 
NYU School of Medicine, USA 
Jin O-Uchi, 
Brown University, USA
*Correspondence:
Vincent Probst  
vincent.probst@chu-nantes.fr
Specialty section: 
This article was submitted to 
Cardiovascular Genetics and 
Systems Medicine, 
a section of the journal 
Frontiers in Cardiovascular Medicine
Received: 11 February 2016
Accepted: 28 March 2016
Published: 25 April 2016
Citation: 
Gourraud J-B, Barc J, Thollet A, 
Le Scouarnec S, Le Marec H, 
Schott J-J, Redon R and Probst V 
(2016) The Brugada Syndrome: A 
Rare Arrhythmia Disorder with 
Complex Inheritance. 
Front. Cardiovasc. Med. 3:9. 
doi: 10.3389/fcvm.2016.00009
The Brugada Syndrome: A Rare 
Arrhythmia Disorder with 
Complex inheritance
Jean-Baptiste Gourraud1, 2, 3, 4 , Julien Barc 2, 3, 4 , Aurélie Thollet1 , Solena Le Scouarnec 2, 3, 4 , 
Hervé Le Marec1, 2, 3, 4 , Jean-Jacques Schott1, 2, 3, 4 , Richard Redon1, 2, 3, 4 and  
Vincent Probst1, 2, 3, 4*
1 Service de Cardiologie, Centre Hospitalier Universitaire (CHU) de Nantes, l’institut du thorax, Nantes, France, 2 Institut 
National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1087, l’institut du thorax, 
Nantes, France, 3 Centre National de la Recherche Scientifique (CNRS) UMR 6291, l’institut du thorax, Nantes, France, 
4 l’institut du thorax, Université de Nantes, Nantes, France
For the last 10  years, applying new sequencing technologies to thousands of whole 
exomes has revealed the high variability of the human genome. Extreme caution should 
thus be taken to avoid misinterpretation when associating rare genetic variants to dis-
ease susceptibility. The Brugada syndrome (BrS) is a rare inherited arrhythmia disease 
associated with high risk of sudden cardiac death in the young adult. Familial inheritance 
has long been described as Mendelian, with autosomal dominant mode of transmission 
and incomplete penetrance. However, all except 1 of the 23 genes previously associated 
with the disease have been identified through a candidate gene approach. To date, 
only rare coding variants in the SCN5A gene have been significantly associated with 
the syndrome. However, the genotype/phenotype studies conducted in families with 
SCN5A mutations illustrate the complex mode of inheritance of BrS. This genetic com-
plexity has recently been confirmed by the identification of common polymorphic alleles 
strongly associated with disease risk. The implication of both rare and common variants 
in BrS susceptibility implies that one should first define a proper genetic model for BrS 
predisposition prior to applying molecular diagnosis. Although long remains the way to 
personalized medicine against BrS, the high phenotype variability encountered in familial 
forms of the disease may partly find an explanation into this specific genetic architecture.
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iNTRODUCTiON
The Brugada syndrome (BrS) is a rare inherited arrhythmia disease, first described in 1992, increas-
ing the risk of ventricular fibrillation in apparently healthy young adults (1). It is suspected to be 
involved in 4–12% of cases of sudden cardiac death (SCD) in the general population and in at least 
20% of SCD in patients with a structurally normal heart (1–3).
Clinical diagnosis is based on a specific electrocardiographic (ECG) pattern defined in three 
consecutive consensus conferences (4–6). This ECG pattern, previously known as “type 1” ECG 
pattern, is defined as a ST segment elevation with a coved-type morphology ≥0.2 mV in one lead 
among the right precordial leads V1 and V2, positioned in the second, third, or fourth intercostal 
space occurring either spontaneously or after provocative drug test with intravenous administra-
tion of Class I antiarrhythmic drugs (6) (Figure 1). The ECG pattern may be transient in affected 
V1 4°ICS
V2 4°ICS
V3 4°ICS
V4 4°ICS
V1 3°ICS
V2 3°ICS
DII
FiGURe 1 | Ajmaline testing reveals the Brugada eCG pattern. ECG pattern is recorded at 1 mm/10 mV and 25 mm/s. Baseline ECG without aspect of BrS 
(left side). Type 1 Brugada pattern on the right precordial leads at the end of the test (right side).
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patients (7). To address this issue, unmasking drugs, such as 
ajmaline, flecainide, and procainamide, can be used to reveal this 
pattern (8), ajmaline showing higher sensitivity than flecainide 
and procainamide (4, 9, 10).
The high variability of the ECG pattern impairs proper assess-
ment of its prevalence in the general population. Epidemiological 
studies have produced heterogeneous results regarding BrS 
incidence across the World. While estimated at 5 for 10,000 in 
western Europe and the USA, the prevalence of BrS seems higher 
in Southeast Asia, reaching 20 for 10,000 (11–13).
Aborted SCD is often the first symptom in BrS, with a mean 
age of 45 years at diagnosis and a four-time higher incidence in 
men than in women (14, 15). A third of the affected patients are 
identified after syncope, frequently preceded by vagal symptoms 
(14). The syncope could either be due to non-sustained VF or 
to a vaso-vagal episode without direct clinical relevance, render-
ing it hard for the practitioner to distinguish arrhythmic from 
 non-arrhythmic etiology (16, 17). The majority of patients are 
asymptomatic at time of diagnosis. More than one-third of cases 
are identified during familial screening (14).
Implantation of a defibrillator is still the only efficient therapy 
in high-risk patients, with a 48% rate of appropriate device 
therapy at 10  years in patients with previous aborted sudden 
death. This rate falls to 12% among implanted asymptomatic 
patients, many affected patients remaining asymptomatic dur-
ing all their life. Furthermore, device-related complications are 
frequent with a 30% risk at 10-year follow-up mainly due to lead 
dysfunction, inappropriate therapy, and infection (18, 19). These 
serious side effects in comparison to the very low arrhythmic risk 
for asymptomatic patients require accurate risk stratification and/
or efficient drug therapy.
Only few clinical parameters allow risk stratification in BrS. The 
effectiveness of ventricular stimulation is still a matter of debate, 
and symptoms and spontaneous ECG pattern are still the two major 
parameters enabling risk stratification for SCD (6, 14, 20–23).
There is still need for medical therapies that could reduce 
arrhythmia occurrence and prevent SCD. Because successful tri-
als were reported in limited series of patients, quinidine has been 
expected to be “the drug” for BrS. However, several recent studies 
failed to demonstrate its beneficial effects (6, 24–27).
FiGURe 2 | The complex inheritance pattern of BrS. Modified from Ref. (41). Incomplete penetrance of the SCN5A mutation is illustrated by the presence of 
unaffected carriers of the mutation (+). The patient highlighted by an ellipse presents with a BrS ECG aspect, despite the absence of the familial mutation. Affected 
family members carrying the SCN5A mutation present with progressive cardiac conduction disease (PCCD) (right half-filled symbol), BrS (left half-filled symbol), or 
both diseases (full-filled symbol). PCCD consists of right bundle branch block with PR interval lengthening and led to complete AVB in three patients, in whom a 
pacemaker (PM) was implanted.
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There is accumulating evidence that implantable defibrillator 
is an effective and accurate therapy for symptomatic patients 
(18). Many clinical parameters have also been proposed for 
asymptomatic patients, but risk prediction in the latter group of 
patients remains particularly challenging because of the lack of 
reproducible and reliable data (28).
TwO PATHOPHYSiOLOGiCAL  
MODeLS FOR BrS
Those unresolved questions concerning diagnosis and risk 
stratification for arrhythmia and therapy underlie the need for a 
better understanding of pathophysiological mechanisms in BrS. 
Two main pathophysiological hypotheses have been proposed to 
explain the ECG pattern.
Soon after the description of BrS, the first pathophysiologi-
cal model was proposed, based on the existence of a transmural 
voltage gradient due to a repolarization heterogeneity across the 
ventricular wall (29, 30). According to this hypothesis, ST seg-
ment elevation could be due to either a loss of function of the 
sodium channel NaV1.5 responsible for the depolarization phase 
(phase 0 of the AP) favoring the expression of repolarization 
heterogeneity, an aggravation of this heterogeneity by a gain of 
function in one of the cardiac potassium channels responsible of 
the repolarization phases (phases 1 and 3 of the AP), or a loss of 
function of the CaV1.2 calcium channel that participate to the 
phase 2 of the AP (29).
This hypothesis has been matter to debate since the second 
hypothesis, based on a conduction delay in the right ventricular 
outflow tract, emerged from clinical observations (31–35). This 
conduction delay could be responsible for voltage gradients 
between RV and RVOT during and explain the BrS ECG pattern.
Twenty years of genetic research based on both technological 
and methodological progresses have started to depict the complex-
ity of BrS pathophysiology (36, 37). This review aims to provide an 
integrated synopsis of those two decades of research and to suggest 
future directions for further genetic investigations against BrS.
FROM A FAMiLiAL DiSeASe TO THe 
iDeNTiFiCATiON OF RARe vARiANTS
With the initial report of two affected siblings, familial inherit-
ance was suggested from the first description of the Brs in 1992 
(1). Few years later, Kobayashi et al. described a two-generation 
family presenting with both SCD and persistent ST elevation 
in relatives (38), confirming the heritability of the disease. The 
genetic component of BrS was further demonstrated in several 
reports (39–41) (Figure  2). Today, familial history of SCD is 
TABLe 1 | The 23 reported susceptibility genes for BrS.
OMiM 
ranking
Gene Protein Prevalence in  
BrS cases
Functional effect  
of the mutation
Reference
BrS1 SCN5A α subunit of the Nav1.5 sodium channel 20–25%  INa (42)
BrS2 GPD1L Glycerol-3-phosphate dehydrogenase 1-like Rare  INa (49)
BrS3 CACNA1C α subunit α1C of the Cav1.2 calcium channel 1–2%  ICa-L (51)
BrS4 CACNB2b β subunit Cavβ2b of calcium channel 1–2%  ICa-L (51)
BrS5 SCN1b β subunit Navβ1 of sodium channel Rare INa (52)
BrS6 KCNE3 β subunit MiRP2 of potassium channel Rare  Ito (53)
BrS7 SCN3b β subunit Navβ3 of sodium channel Rare  INa (54)
BrS8 HCN4 Hyperpolarization-activated cyclic nucleotide-gated channel 4 Rare ? (55)
BrS9 KCND3 α subunit of the KV4.3 potassium channel Rare  Ito (56)
BrS10 KCNJ8 α subunit of the KIR6.1 potassium channel Rare  IKATP (57)
BrS11 CACNA2D1 δ subunit Cavα2δ1 of calcium channel Rare  ICa-L (58)
BrS12 KCNE5 β subunit of potassium channel Rare  Ito (59)
BrS13 RANGRF RAN guanine nucleotide release factor Rare  INa (60)
BrS14 KCND2 α subunit of the KV4.2 potassium channel Rare  Ito (61)
BrS15 TRPM4 Calcium-activated non-selective ion channel Rare ? (62)
BrS16 SCN2B β subunit Navβ2 of sodium channel Rare  INa (63)
BrS17 PKP2 Plakophilin 2 Rare  INa (64)
BrS18 ABCC9 ATP-sensitive potassium channels Rare  IKATP (65)
BrS19 SLMAP Sarcolemma-associated protein Rare  INa (66)
BrS20 KCNH2 α subunit of the HERG potassium channel Rare  IKr (67)
BrS21 SCN10A α subunit of the Nav1.8 sodium channel <5%  INa (68, 69)
BrS22 FGF12 Fibroblast growth factor 12 Rare  INa (70)
BrS23 SEMA3A Semaphorin family protein Rare  Ito (71)
Functionnal effect on current are described with arrow, except for HCN4 mutation for which it remain unclear (?).
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reported for about 26% of affected patients. Additionally, 36% 
of affected patients are identified during familial screening after 
SCD or identification of BrS in the proband (14).
Brugada syndrome has been consistently reported as a 
monogenic disease with autosomal dominant mode of inherit-
ance, caused by rare genetic variants with large effect size (1, 38). 
Loss-of-function mutations in the SCN5A-encoded α-subunit 
of the cardiac sodium channel (Nav1.5) were first identified in 
1998 (42). Mutations in SCN5A are detected in 20–25% of cases, 
SCN5A appearing as the major susceptibility gene for BrS (43). 
More than 300 rare variants in SCN5A have been reported, while 
the contribution of other genes remains extremely low (43, 44). In 
a pediatric population affected by BrS, the prevalence of SCN5A 
mutations seems to be even higher (45).
In this context, genetics was initially expected to help the 
clinical management of patients with BrS. Although some SCN5A 
mutations – particularly those leading to premature truncation of 
Nav1.5 – have been reported as associated with higher arrhythmic 
risk, no such result has been further confirmed in randomized 
studies (14, 46–48).
Despite evidence for strong familial inheritance, familial 
linkage analyses on BrS have been largely unsuccessful. Only one 
gene, GPD1L, has been identified as a BrS-susceptibility gene 
using this approach (49). The causing mutation in GPD1L has 
been shown to affect Na+ channel trafficking to the plasma mem-
brane, by modifying its oxydation state (49, 50). Every other gene 
reported so far has been identified through a candidate approach 
based on direct sequencing of genes with a known (or suspected) 
role in cardiac electrical activity.
So far, 23 genes have been related to BrS (Table  1). Based 
on pathophysiological hypotheses, those genes can be divided 
according to whether they affect the sodium current INa (SCN5A, 
SCN10A, GPD1L, SCN1B, SCN3B, RANGRF, SCN2B, PKP2, 
SLMAP, and FGF12), the potassium current IK (KCNJ8, KCNH2, 
KCNE3, KCND3, KCNE5, KCND2, SEMA3A, and ABCC9), or the 
calcium current ICa (CACNA1C, CACNB2B, and CACNA2D1).
LiMiTS iN iNTeRPReTiNG RARe 
vARiANTS CARRieD BY  
PATieNTS wiTH BrS
In the last decade, the emergence of massively parallel sequencing 
[or next-generation sequencing (NGS)] has considerably facili-
tated genetic screening and reduced its cost (72–76). Combined 
to the availability of the reference assembly of the human genome 
(77, 78), NGS-based approaches have revealed the high variability 
of the human genome, with at least 300–600 functional genetic 
variants detected in each exome (i.e., the whole coding portion of 
a single genome) (75) – and has retrospectively changed the inter-
pretation of previous rare variants identified by candidate gene 
approach. The investigation of large number of exomes revealed 
the extraordinary prevalence of rare variants among each indi-
vidual. As an illustration, the sequencing of 60,706 exomes identi-
fied about 7,500,000 variants from which 99% have a frequency of 
<1% (http://biorxiv.org/content/early/2015/10/30/030338).
Extreme caution should thus be taken when interpreting the 
rare genetic variants detected among patients with BrS, since the 
FiGURe 3 | The distribution of rare coding variants detected across four selected arrhythmia-susceptibility genes among 167 BrS cases and 167 
healthy individuals. Modified from Ref. (44). SCN5A (A), SCN10A (B), CACNA1C (C), and PKP2 (D) are the four genes exhibiting the largest numbers of rare 
coding variants among BrS cases. Rare coding variants (minor allele frequency <0.1%) are represented in red (cases) and blue (controls). Green variants are 
detected in both cases and controls.
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clinical implication of finding those variants remains doubtful in 
the absence of statistical association and/or of evidence support-
ing a functional effect in relation with cardiac electrical activity 
(79–82).
Furthermore, a recent study has illustrated the weakness of 
candidate approaches on small pedigrees, by highlighting the high 
frequency of some genetic variants previously associated with 
BrS among 6,500 individual exomes from the Exome Sequencing 
Project (83). One variant in particular, which was related to BrS 
based on functional evidence, showed a minor allele frequency of 
4.4% among the 6,500 individuals. This result was confirmed in a 
healthy Danish control population, suggesting that a proportion 
of the genetic variants reported as causing BrS are actually not 
pathogenic. Interestingly, 93% of the SCN5A variants reported as 
causing BrS are not present among the control population, thus 
reinforcing the pivotal role of this gene.
By testing the burden of rare coding variants in 45 arrhythmia-
susceptibility genes among 167 BrS cases versus 167 control 
individuals, we have also recently demonstrated the limitation 
of previous candidate approaches (44). Indeed, for every tested 
gene except SCN5A, rare variants were found in the same propor-
tion in cases than in controls. Figure 3 shows the distribution of 
rare variants among cases and controls for the protein products 
of four genes: SCN5A, SCN10A, CACNA1C, and PKP2. The 
distribution of rare variants across the functional domains of the 
CACNA1C product indicates that the C-terminal tail, which was 
previously considered as pathogenic in BrS, may in fact be highly 
polymorphic. On the opposite, most rare variants detected along 
the protein encoded by PKP2 among BrS patients reside in a small 
interval coding for four amino acids. The PKP2 gene has been 
previously associated with BrS by decreasing functional Na chan-
nel expression through modification of microtubule anchoring 
(64). The small PKP2 interval emphasized in this study may be a 
preferential site of such interaction.
Rare genetic variants appear more evenly distributed across 
SCN10A and less predictive of any potential pathophysiological 
mechanism. In fact, the functional effects of these rare variants 
affecting SCN10A are largely debated. SCN10A gene, which 
encodes the sodium channel Nav1.8, was initially described in 
neurons physiology (84, 85). Further investigations illustrated a 
potential role in cardiac electrophysiology, particulary as a modu-
lator of cardiac conduction (86, 87). Recently, Hu et al. described 
rare variants in the SCN10A gene, in 16.7% of 150 patients 
affected with BrS (68). Furthermore, they demonstrated that the 
SCN10A variants R1268Q and R14L reduced cardiac sodium 
currents (68). However, although relevant biological effects are 
reported for some variants, most variants are also reported in 
control populations. Behr et  al. have recently underlined this 
issue (69). Using an extended control population, they decreased 
the yield of such variants from 16.7% in the Hu et al.’s study to 
5.1% in a different set of BrS probands (68). Additionally, only 
two over seven familial pedigrees available with such variants 
demonstrated segregation with the BrS.
Coding genetic variants in candidate genes are usually clas-
sified as likely pathogenic if they are extremely rare or absent 
from control populations. However, private genetic variants are 
found in control populations, and many rare variants predicted as 
damaging are carried by apparently healthy individuals (44, 83). 
As an example, in the SCN5A gene, rare functional variants 
can be found in about 2% of control patients and even in 5% in 
non-white population (88). Thus, considering SCN5A-mediated 
BrS account for about 20% of cases and that background noise 
of rare variant with minor allele frequency under 1/10,000 is 
approximately 2%, there is a 10/1 signal to noise ratio that means 
a 10% risk of false positive in possibly damaging rare SCN5A 
variants (82). As prevalence of asymptomatic BrS in the general 
population is unknown, this percentage may be over estimated. 
However, as BrS is a rare disease, the proportion of false positive 
6Gourraud et al. Genetics of Brugada Syndrome
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variants remains, in any case, too high to be confident with a 
direct translation of new rare variants in clinical practice.
On the opposite, some rare variants detected among BrS 
patients are reported as benign by prediction algorithms though 
they modify the function of the protein. As an example, while 
one SCN3B variant has been associated with BrS and reported as 
impacting the sodium current density, it is considered as benign 
by prediction algorithms such as SIFT and PolyPhen-2 (54, 89, 
90). This demonstrates the strong limitations of such prediction 
algorithms and the need for functional studies and/or segregation 
analyses to better assess the causality of rare variants.
From that perspective, mutations in L-type calcium channels 
(CACNA1C, CACNB2B, and CACNA2D1) that were considered 
as associated with about 4% of BrS cases are of particular inter-
est (43). The L-type calcium current ICa-L is a perfect candidate 
to explain BrS physiopathology, due to its central role in action 
potential dome (phases 2 and 3) and in the “depolarization” 
hypothesis (91). However, functional studies on mutations in 
L-type calcium channels are scarce in the literature. Moreover, 
mutations in CACNA1C among BrS cases and controls are mostly 
located within the C-terminal tail of Cav1.2, thus suggesting a high 
genetic variability of the domain (Figure 3). Although CACNA1C 
mutations seem to play lesser role than previously reported, this 
particular gene remains involved in a small subset of BrS cases, 
in particularly those with combined phenotypes of BrS and short 
QT syndrome (92).
These accumulated data demonstrate that in order to avoid 
misinterpretation of genetic variants: (1) functional prediction 
algorithms should be used cautiously and (2) ancestry-matched 
control populations should be systematically considered. 
Furthermore, familial segregation analysis and/or extended 
functional testing are mandatory before associating rare coding 
variants to disease susceptibility.
Following these guidelines, no previously reported suscep-
tibility gene except SCN5A seems to contribute significantly to 
BrS pathophysiology. Although SCN5A remains the major gene 
involved in BrS with about 20% of carriers among probands 
(43, 44), a proportion of rare variants residing in this gene – par-
ticularly among those of uncertain functional effect – could play 
no role in relation with the disease (82).
THe COMPLeX iNHeRiTANCe OF BrS: 
TOwARD A New GeNeTiC MODeL
Since the discovery of SCN5A as the first susceptibility gene for 
BrS, this disorder has been consistently reported as a monogenic 
disease with autosomal dominant mode of inheritance, caused 
by rare genetic variants with large effect size (1, 38, 42). SCN5A 
remains the only major susceptibility gene for BrS, with more 
than 300 coding variants described among more than 75% of the 
genetically diagnosed patients (43, 93). However, hardly any of the 
large family pedigrees with BrS provides evidence for Mendelian 
inheritance. Most familial forms indicate a genetic model with 
incomplete penetrance and remain genetically undiagnosed.
We have investigated the cosegregation of SCN5A mutations 
with BrS among large genotyped families (41). SCN5A mutations 
exhibit low penetrance (61% after drug testing) in families, lead-
ing to poor genotype/phenotype correlations. More surprisingly, 
among five pedigrees, we could identify eight affected members 
who did not carry the familial SCN5A mutation (Figure 2). This 
lack of genotype/phenotype correlation is further emphasized in 
other families with variable cardiac phenotypes associated with a 
same SCN5A mutation. Indeed, although a Na current decrease 
could lead to cardiac conduction or sinus node dysfunction, the 
description of relatives sharing the same SCN5A mutation but 
presenting with either BrS or a progressive cardiac conduction 
disease question about the relevance of a monogenic model 
(94, 95). A similar issue involving SCN5A mutation has been 
described with BrS and long QT syndrome (96).
These observations have led us to seek for genetic factors 
modulating the risk of Brugada ECG phenotype. To explore 
the potential role of common genetic variants in susceptibility 
to Brs, we have recently coordinated an international genome-
wide association study (GWAS) on BrS. By comparing allele 
frequencies of common haplotypes genome wide among 312 
index cases versus 1,115 control individuals, we identified three 
loci associated with susceptibility to BrS (Figure 4A). The three 
hits were then replicated on independent case–control sets from 
Europe and Japan. We found that their cumulative effect on 
disease susceptibility was unexpectedly large, with an estimated 
odds ratio of 21.5 in the presence of more than four risk alleles 
versus less than two (Figure 4B). This study demonstrates that an 
aggregation of genetic polymorphisms can strongly influence the 
susceptibility to BrS and confirms that the mode of inheritance 
for this arrhythmia disorder is far more complex than previously 
described.
Two association signals reside at the SCN5A-SCN10A locus. 
Both common risk alleles have previously been associated with 
cardiac conduction traits in the general population (97). This 
finding demonstrates that genetic polymorphisms modulating 
cardiac conduction can also influence susceptibility to cardiac 
arrhythmia. One haplotype is located inside the SCN10A gene, of 
which involvement in the pathophysiology of BrS is still matter 
to debate. van den Boogaard et  al. provided evidence that the 
SCN10A haplotype contain was an enhancer region for both 
SCN10A and SCN5A genes (98). They further demonstrated 
that a common variant (rs6801957) of this locus, associated 
with cardiac conduction trait and in high linkage disequilibrium 
with rs10428132, alters a transcription factor binding site for 
TBX3/TBX5 and reduces the SCN5A expression (99). This may 
explain the high phenotype variability observed in BrS patients 
even within a same family.
The third association signal resides near the Hey2 gene, 
which encodes a basic helix-loop-helix transcriptional repressor 
expressed in the cardiovascular system. The implication of this 
gene in susceptibility to BrS was previously unknown (100). 
Interestingly, Hey2 presents a gradient of expression across the 
ventricular wall in mirror image with SCN5A expression suggest-
ing a possible (indirect) regulation mechanism. Despite no ECG 
changes, Hey2 heterozygous knockout mice (Hey2+/−) present 
interesting findings for BrS pathophysiology. Conduction veloc-
ity seems specifically increase in the right outflow tract in which 
cellular action potential present both increase in AP upstroke 
FiGURe 4 | A genome-wide association study on BrS. Modified from Ref. (101). (A) Manhattan plot revealing signal associations between two SNP (SCN10A 
and HEY2) and BrS. Statistical significance is represented with a red line (P = 5 × 10−8). A third haplotype of SCN5A reached genome-wide significance after 
replication analysis. (B) The cumulative effect of the six common risk alleles on susceptibility to BrS. Odds Ratio (OR) is plotted on the vertical axis and the 
cumulative number of alleles (from 0 to 6) in horizontal axis.
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velocity and repolarization (101). These data uncovered the role 
of Hey2 in the cardiac electrical function and more specifically in 
the pathogenesis of BrS. Among its role on BrS phenotype, com-
mon variant in this gene could also presented with a protective 
role from ventricular fibrillation in BrS patients by regulating the 
repolarization current (102).
CONCLUSiON
Almost two decades ago, the first description of a mutation in 
SCN5A gene has paved the way of genetics in BrS. As BrS was 
initially described as a Mendelian disease with low penetrance, 
many studies have been performed to track genetic variants in 
families affected by this syndrome. However, in most cases, stud-
ies were unable to show positive linkage. In a very large majority of 
cases, putative causing genes were identified through a “candidate 
gene approach” based on pathophysiological hypotheses. In these 
a priori approaches, the results were “validated” by the rarity of 
the genetic variants identified, while aberrant linkage results were 
“explained” by non-penetrance or phenocopies.
In the recent years, NGS technologies have dramatically 
expanded our capacity to sequence genomes. It has also revealed 
the high variability of the human genome, underlying the 
extreme caution that should be taken to avoid misinterpreta-
tion of the potential association of rare variants with BrS. Thus, 
recent burden tests have questioned the implication of several 
genes previously identified as there distribution was similar in 
the normal population and affected patients. For now, only rare 
variants in SCN5A gene seem to be significantly associated with 
the syndrome.
However, genotype/phenotype studies among BrS families 
with SCN5A mutation carriers have highlighted a complex mode 
of inheritance for this syndrome. In line with these reports, a 
GWAS has recently identified three common risk haplotypes for 
the Brugada ECG pattern.
It is now established that the molecular mechanisms leading to 
BrS involve both rare and common genetic variants, underlying 
the need for better understanding the genetic architecture of BrS 
prior to applying genetics as a diagnostic tool. For the next future, 
one of the challenges that could contribute to a more efficient 
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strategy for BrS would be to decipher the role of the combination 
of variants both for diagnosis and prognosis.
Another source of progress regarding risk stratification among 
BrS patients could go through the identification of specific ECG 
indices associated with higher risk of (fatal) arrhythmia. Genetic 
variants at the SCN5A, HEY2, and SCN10A loci have been associ-
ated with arrhythmia occurrence in independent studies (47, 102, 
103). Integrating such effects toward establishing a global genetic 
model for BrS is the next step before including genetic testing into 
the clinical management of BrS.
Besides the direct benefit of this research on the BrS for itself, 
it appears increasingly that this primary electrical disorder affect-
ing the young adult (with no identifiable structural abnormalities 
and presenting limited exposure to environment side effect) may 
represent a relevant model for the identification of markers and 
mechanism implied into broader common cardiac arrhythmias. 
Retrospectively, SCN10A common variant identified in the BrS 
GWAS study have been also associated with the risk of VF in 
the context of myocardial infarction and with the pacemaker 
implantation rate (103, 104). Additionally, a protective role 
against developing AF has been suggested for both common vari-
ants previously identified as risk alleles for BrS at the SCN10A–
SCN5A locus. This reinforces the interest of rare diseases to help 
identifying the pathophysiological bases of common pathologies. 
As they constitute homogenous groups of patients, rare arrhyth-
mia disorders can provide new molecular insights that may be 
relevant to the broader health issue of SCD (105).
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